Crestline Management, L.P.
CIK 1536054
13F filing for Q2 2026・No. 3,735
- Holdings
- US$534.76M
- Quarter change
- +US$488.49M
- Entries
- 3
- Net bought (estimate)
- −US$7.72M
The quarter change is the holdings' value against the quarter before, price moves included — not what was bought or sold; each institution's page estimates that.
Net bought (estimate)
Each stock's change in shares at the quarter-end price, added up: a new position counts as bought, one sold out as sold, shares held long only. Splits are compared split-adjusted; corporate actions under a new CUSIP are not estimated. An estimate from the filings, not actual trades.
- New 0
- Sold out 0
- Cut 1
- Added 0
- Corporate actions 0
- Unchanged 2
Largest holdings
3 stocks worth US$53.48M, options and bonds left out.
| Stock | This quarter | Shares | Value | Weight |
|---|---|---|---|---|
| DNLIDENALI THERAPEUTICS INCCOM | Cut | 1,910,732 | US$49.14M | 91.90% |
| SANA BIOTECHNOLOGY INCCOM | Unchanged | 755,736 | US$2.64M | 4.93% |
| 8X8 INC NEWCOM | Unchanged | 990,850 | US$1.69M | 3.17% |
Sign in (free) to see its 3 largest holdings and its trades. Sign in
Filings
The quarter's original 13F filings (SEC).
- 13F-HRFiled August 14, 2026SEC ↗
13F covers long positions in US-listed securities only; the data is SEC's, filed within 45 days of the quarter's end.